Garcia-Manero G - Search Results

1

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).

Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Raza A, et al. J Hematol Oncol. 2012 Apr 30;5:18. doi: 10.1186/1756-8722-5-18. J Hematol Oncol. 2012. PMID: 22546242 Free PMC article. Clinical Trial.

2

Evaluating new treatment options for MDS.

Garcia-Manero G, Yang AS, Jagasia M. Garcia-Manero G, et al. Clin Adv Hematol Oncol. 2007 Nov;5(11):1-9; quiz 10-2. Clin Adv Hematol Oncol. 2007. PMID: 18185491 Review.

3

Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.

Stone R, Sekeres M, Garcia-Manero G, Lyons RM. Stone R, et al. Clin Adv Hematol Oncol. 2008 Dec;6(12):1-15. Clin Adv Hematol Oncol. 2008. PMID: 19385003

4

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Steensma DP, et al. J Clin Oncol. 2009 Aug 10;27(23):3842-8. doi: 10.1200/JCO.2008.19.6550. Epub 2009 Jun 15. J Clin Oncol. 2009. PMID: 19528372 Free PMC article. Clinical Trial.

5

Evolving strategies in the treatment of MDS and AML.

Stone R, Sekeres M, Garcia-Manero G. Stone R, et al. Clin Adv Hematol Oncol. 2009 Aug;7(8):1-14; quiz 2 p following 14. Clin Adv Hematol Oncol. 2009. PMID: 19927982

6

Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.

Wang SA, Jabbar K, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. Wang SA, et al. Leukemia. 2010 Apr;24(4):740-7. doi: 10.1038/leu.2009.289. Epub 2010 Jan 14. Leukemia. 2010. PMID: 20072149

7

Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.

Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, Garcia-Manero G, Miranda RN. Wang SA, et al. Leuk Res. 2011 Mar;35(3):351-7. doi: 10.1016/j.leukres.2010.07.018. Epub 2010 Aug 5. Leuk Res. 2011. PMID: 20691474

8

Clinical effect of point mutations in myelodysplastic syndromes.

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Bejar R, et al. N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJMoa1013343. N Engl J Med. 2011. PMID: 21714648 Free PMC article.

9

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.

Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. Patnaik MM, et al. Blood. 2012 Jan 12;119(2):569-72. doi: 10.1182/blood-2011-09-377994. Epub 2011 Nov 17. Blood. 2012. PMID: 22096241 Free PMC article.

10

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.

Garcia-Manero G. Garcia-Manero G. Am J Hematol. 2012 Jul;87(7):692-701. doi: 10.1002/ajh.23264. Am J Hematol. 2012. PMID: 22696212 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,013 results

Search Page

Filters